Journal
BLOOD
Volume 117, Issue 26, Pages 6987-6990Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-340273
Keywords
-
Categories
Funding
- National Institutes of Health [P50 CA100632-06, R01 CA128864)]
- ASCO Foundation
Ask authors/readers for more resources
Acute myeloid leukemia with a FLT3 internal tandem duplication (FLT3/ITD) mutation is an aggressive hematologic malignancy with a generally poor prognosis. It can be successfully treated into remission with intensive chemotherapy, but it routinely relapses. At relapse, the blasts tend to have higher mutant allelic ratios and, in vitro, are more addicted to the aberrant signaling from the FLT3/ITD oncoprotein. They remain highly responsive to FLT3 ligand, the levels of which rise several-fold during the course of chemotherapy. The question now arises as to whether these high levels of FLT3 ligand are actually promoting relapse, and, if so, how we can use this information to adjust our therapeutic approach and improve the cure rate for acute myeloid leukemia with FLT3/ITD. (Blood. 2011;117(26):6987-6990)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available